Bcal Diagnostics Ltd Cash Flow Conversion Efficiency

Latest as of June 2026: 4.435x

Bcal Diagnostics Ltd cash flow conversion efficiency. Based on the latest financial reports, Bcal Diagnostics Ltd (BDX) has a cash flow conversion efficiency ratio of 4.435x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-3.66 Million ≈ $-2.59 Million USD) by net assets (AU$-826.19K ≈ $-584.58K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Bcal Diagnostics Ltd (2017–2025)

Cash flow conversion efficiency of Bcal Diagnostics Ltd from 2017 to 2025. This chart illustrates how Bcal Diagnostics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Bcal Diagnostics Ltd stock quote for real-time trading data and today's change.

Bcal Diagnostics Ltd Cash Flow Conversion Ratio Explained

Bcal Diagnostics Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Bcal Diagnostics Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Bcal Diagnostics Ltd ranked by their cash flow conversion efficiency. Also see BDX market cap for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Alpha Group International plc LSE:ALPH	-0.074x
MNC Vision Networks PT JK:IPTV	0.015x
Agroton Public Ltd. WAR:AGT	-0.142x
OCB Bhd KLSE:5533	0.057x
Country Club Hospitality & Holidays Limited NSE:CCHHL	0.014x
INTERSHOP Communications Aktiengesellschaft XETRA:ISHA	0.244x
Crypto Blockchain Industries SA PA:ALCBI	-0.428x
ISA Holdings Ltd JSE:ISA	0.239x

Annual Cash Flow Conversion Efficiency for Bcal Diagnostics Ltd (2017–2025)

The table below shows the annual cash flow conversion efficiency of Bcal Diagnostics Ltd from 2017 to 2025. Review Bcal Diagnostics Ltd free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	AU$-826.19K ≈ $-584.58K	AU$-6.16 Million ≈ $-4.36 Million	7.456x	+855.93%
2024-12-31	AU$6.22 Million ≈ $4.40 Million	AU$-6.14 Million ≈ $-4.34 Million	-0.986x	-87.28%
2023-12-31	AU$8.59 Million ≈ $6.08 Million	AU$-4.52 Million ≈ $-3.20 Million	-0.527x	+54.60%
2022-12-31	AU$5.21 Million ≈ $3.69 Million	AU$-6.05 Million ≈ $-4.28 Million	-1.160x	-247.35%
2021-12-31	AU$9.64 Million ≈ $6.82 Million	AU$-3.22 Million ≈ $-2.28 Million	-0.334x	+0.16%
2020-12-31	AU$3.61 Million ≈ $2.55 Million	AU$-1.21 Million ≈ $-853.62K	-0.334x	+77.81%
2019-12-31	AU$438.92K ≈ $310.56K	AU$-661.65K ≈ $-468.16K	-1.507x	-40.18%
2018-12-31	AU$488.20K ≈ $345.43K	AU$-525.01K ≈ $-371.48K	-1.075x	-118.70%
2017-12-31	AU$-81.85K ≈ $-57.91K	AU$-470.81K ≈ $-333.13K	5.752x	--

About Bcal Diagnostics Ltd

AU:BDX Australia Diagnostics & Research

Market Cap

$21.91 Million

AU$30.97 Million AUD

Market Cap Rank

#24673 Global

#996 in Australia

Share Price

AU$0.08

Change (1 day)

+5.00%

52-Week Range

AU$0.05 - AU$0.14

All Time High

AU$0.25